New Zealand-based Upside Biotechnologies has launched a new skin replacement treatment in Auckland for patients suffering from major burns.
Using regenerative medicine, new methods can be developed to regrow, repair or replace damaged or diseased cells, organs or tissues to restore or establish normal function.
Go deeper with GlobalData
Upside Biotechnologies has developed the new technology at the University of Auckland’s Rod Dunbar’s laboratory.
Upside Biotechnologies CEO Dr Robert Feldman said: “Upside skin is produced faster than any competitive product in development, and is supplied in larger sheets with excellent handling characteristics that burns surgeons prefer.”
The company has completed a first tranche of equity funding and is currently seeking further investment.
To date, the work has received funding from Cure Kids Ventures, Auckland UniServices, the Manchester Trust, the Ministry of Business, Innovation and Employment and The Maurice Wilkins Centre.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUpside’s new technology enables a small sample of unburnt patient skin to be grown in the laboratory into large areas of full thickness skin, which can be used as skin grafts in patients suffering severe burns.
Cure Kids Ventures CEO Maxine Simmons said: “This is a hugely attractive business opportunity.
“A truly compelling healthcare solution that comes from great science and is being run by a world-class team.”
Feldman added: “The technology is superb, the market attractive and backers excellent.”
